Global Pharmaceutical Markets

• Publication date: May 2008

Reviews global markets for prescription and over-the-counter therapeutic drugs and forecasts sales through 2012. Analyzes epidemiological, technological, drug development, regulatory, and competitive factors expected to influence drug sales and offers a qualitative as well as quantitative picture of the world pharmaceutical market in 2012. Discusses epidemiology, treatment algorithms, and relevant major manufacturers for each indication, accompan...

Reviews global markets for prescription and over-the-counter therapeutic drugs and forecasts sales through 2012. Analyzes epidemiological, technological, drug development, regulatory, and competitive factors expected to influence drug sales and offers a qualitative as well as quantitative picture of the world pharmaceutical market in 2012. Discusses epidemiology, treatment algorithms, and relevant major manufacturers for each indication, accompanied by an analysis of current sales, major trends and future sales within this indication. Indications include cardiovascular disease, cancer, diabetes, depression and anxiety, infectious diseases, and others. Drug classes selected for analysis include cholesterol and triglyceride reducers, anti-ulcerants, antidepressants, antirheumatic non-steroidals, antipsychotics, calcium antagonists, erythropoeitins, ACE inhibitors, selected anti-cancer therapeutics, and others. Covers novel therapeutic monoclonal antibodies, therapeutic vaccines, stem cell products, and engineered therapeutic foods. The report discusses both expected and alternative scenarios for selected drug classes. Includes market shares, competitive analysis, regulatory considerations, patent analyses, and complete company profiles.  
 

Pharmaceutical Industry

MAY 2008

INTRODUCTION

STUDY GOALS AND OBJECTIVES

REASONS FOR DOING THE STUDY

AUDIENCE FOR THE REPORT

SCOPE AND FORMAT

METHODOLOGY AND INFORMATION SOURCES

BCC INFORMATION AND RELATED BCC STUDIES

AUTHOR’S CREDENTIALS

BCC ONLINE SERVICES

DISCLAIMER

SUMMARY

AGING POPULATIONS AND CHRONIC DISEASES

OVERALL GLOBAL PHARMACEUTICAL MARKETS

SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, THROUGH 2013 ($ BILLIONS)

SUMMARY FIGURE WORLDWIDE MARKET PHARMACEUTICAL PRODUCTS, 2006-2013 ($ BILLIONS)

OVERVIEW

BACKGROUND ON THE INDUSTRY

RECENT HISTORY

BENEFITS, PROBLEMS, AND REGULATION

CHANGES IN THE INDUSTRY

HEALTHCARE EXPENDITURES

TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS REPORT, 2000 AND 2005 (% OF GDP)

THE PHARMACEUTICAL INDUSTRY

TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007 ($ BILLIONS)

RESEARCH AND DEVELOPMENT EXPENDITURES

TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY R&D SPENDING, 2006 AND 2007 ($ BILLIONS)

SECTOR PERFORMANCE

BRANDED PHARMACEUTICALS

TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)

TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)

TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)

TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND 2007 ($ BILLIONS, % OF TOTAL)

UNITED STATES

INTRODUCTION

TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)

FIGURE 1 U.S. POPULATION, 1998-2013 (MILLIONS)

TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)

THE U.S. HEALTHCARE SYSTEM

HEALTHCARE EXPENDITURES IN THE U.S

FIGURE 2 U.S. HEALTHCARE EXPENDITURES, 1980-2006 ($ BILLIONS)

TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006

TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004 ($ BILLIONS, %)

TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006 ($ BILLIONS)

COMMON HEALTH PROBLEMS IN THE U.S.

TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)

ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS

OBESITY AND RELATED CONDITIONS

DIABETES

CARDIOVASCULAR DISEASE

TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)

SMOKING

CANCER

TABLE 16 INVASIVE CANCER, U.S., 2004 (%)

TABLE 16 (CONTINUED)

TABLE 17 CANCER DEATHS, U.S., 2004 (%)

TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW CASES)

HIV INFECTION

GOVERNMENT REGULATIONS

INTRODUCTION

DRUG DISCOVERY

Preclinical Testing and Submission of an IND

CLINICAL TRIALS

TIMELINE AND COSTS

SUBMISSION OF AN NDA OR BLA

POST-FDA APPROVAL

NEW DRUG APPROVALS

FIGURE 3 NME APPROVALS, 1997-2007

FIGURE 4 NME APPROVALS IN TWO SEVEN-YEAR PERIODS, 1994-2007

TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA, 1980 TO MARCH 20, 2007

DO CURRENT CORPORATE MANAGEMENT PRACTICES HAVE A ROLE IN R&D SHORTFALLS?

BLOCKBUSTER DRUGS

TABLE 20 NME APPROVALS BY DISORDER, 2004-MARCH 20, 2008

OTHER SUCCESSFUL THERAPEUTIC AGENTS

TABLE 21 BOTOX SALES, 1993-2012 ($ MILLIONS)

IS THE NIH FUNDING CRISIS CONTRIBUTING TO SHORTFALLS IN DRUG DISCOVERY?

PHARMACEUTICAL PRICING

FACTORS AFFECTING DRUG PRICES

PHARMACY BENEFIT MANAGERS (PBMS)

TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007 (%)

Pharmacy Benefit Managers … (Continued)

PHARMACEUTICAL FLOW FROM MANUFACTURER TO PATIENT

PHARMACEUTICAL WHOLESALING

TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (%, $ BILLIONS)

PHARMACEUTICAL RETAILING

TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND 2007 (RX MILLIONS)

EXPORT-IMPORT PROFILE

TABLE 25 EXPORT-IMPORT PROFILE, U.S., 1995-2006 ($ BILLIONS)

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)

TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 ($ BILLIONS)

GENERIC DRUGS

TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)

OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.S.

TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013 ($ BILLIONS)

IMPORTANT ORGANIZATIONS IN THE U.S

PHRMA, THE PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

GPHA, GENERIC PHARMACEUTICAL ASSOCIATION

CHPA (CONSUMER HEALTHCARE PRODUCTS ASSOCIATION)

COMPANY PROFILES: UNITED STATES

ABBOTT LABORATORIES

BIOGEN IDEC

AMGEN

BRISTOL-MYERS SQUIBB

FOREST LABORATORIES

GENENTECH

GENZYME

JOHNSON & JOHNSON

ELI LILLY AND COMPANY

MERCK & CO. INC

PFIZER

WYETH PHARMACEUTICALS

TEVA PHARMACEUTICALS

Teva North America

CANADA

INTRODUCTION

TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013 (MILLIONS)

FIGURE 5 CANADA: POPULATION 1998-2013 (MILLIONS)

TABLE 32 DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013 (MILLIONS)

THE CANADIAN HEALTHCARE SYSTEM

HEALTHCARE EXPENDITURE IN CANADA

TABLE 33 HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005

COMMON HEALTH PROBLEMS IN CANADA

ALZHEIMER’S DISEASE AND RELATED DEMENTIAS

OBESITY AND RELATED CONDITIONS

DIABETES

CARDIOVASCULAR DISEASE AND CANCER

HIV INFECTION

PHARMACEUTICAL PRICING

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 34 BRANDED PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)

GENERIC DRUGS

TABLE 35 GENERIC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)

OVER-THE-COUNTER (OTC) MEDICATIONS IN CANADA

TABLE 36 OTC PHARMACEUTICAL MARKET, CANADA, THROUGH 2013 ($ BILLIONS)

TABLE 37 TOP SELLING CATEGORIES OF OTC MEDICATIONS IN CANADA (%)

IMPORTANT ORGANIZATIONS IN CANADA

STATISTICS CANADA

RX&D, CANADA’S RESEARCH-BASED PHARMACEUTICAL COMPANIES

CGPA (CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION)

NDMAC (THE NONPRESCRIPTION DRUG MANUFACTURERS ASSOCIATION OF CANADA)

COMPANY PROFILES: CANADA

ABBOTT LABORATORIES, LIMITED

ACTELION

ASTRAZENECA CANADA INC.

BAYER, INC

BRISTOL-MYERS SQUIBB CANADA

ELI LILLY CANADA INC.

GLAXOSMITHKLINE INC.

HOFFMANN-LA ROCHE LIMITED

LUNDBECK CANADA INC.

MERCK FROSST CANADA LTD

NOVARTIS PHARMACEUTICALS CANADA INC.

PFIZER CANADA INC.

PURDUE PHARMA (1956)

SANOFI-AVENTIS CANADA

SOLVAY PHARMA INC

WYETH PHARMACEUTICALS

Wyeth Pharmaceuticals (continued)

MEXICO

INTRODUCTION

TABLE 38 OVERALL PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 39 POPULATION TRENDS, MEXICO, THROUGH 2013 (MILLIONS)

THE MEXICAN HEALTHCARE SYSTEM

HEALTHCARE EXPENDITURE IN MEXICO

TABLE 40 HEALTHCARE EXPENDITURE: MEXICO, 2000-2005

COMMON HEALTH PROBLEMS IN MEXICO

OBESITY AND RELATED CONDITIONS

DIABETES: THE LEADING CAUSE OF DEATH

HIV INFECTION

PHARMACEUTICAL REGULATION AND PRICING

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 41 BRANDED PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)

GENERIC DRUGS

TABLE 42 GENERIC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)

OVER-THE-COUNTER (OTC) MEDICATIONS IN MEXICO

TABLE 43 OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH 2013 ($ BILLIONS)

IMPORTANT ORGANIZATIONS IN MEXICO

STATISTICS MEXICO: SISTEMAS NACIONALES ESTADÍSTICO Y DE INFORMACIÓN GEOGRÁFICA (SNEIG)

AFAMELA (ASOCIACION DE FABRICANTES DE MEDICAMENTOS DE LIBRE ACCESO AC)

AMIIF (ASOCIACIÓN MEXICANA DE INDUSTRIALES DE INVESTIGACIÓN FARMACÉUTIA A.C., MEXICAN

ASSOCIATION OF PHARMACEUTICAL COMPANIES)

CANIFARMA (CAMARA NACIONAL DE LA INDUSTRIA FARMACEUTICA)

FIFARMA, THE LATIN AMERICAN FEDERATION OF THE PHARMACEUTICAL INDUSTRY

ILAR (INDUSTRIO LATINOAERMICANA DE AUTOMEDICACION RESPONSABLE)

BRAZIL

INTRODUCTION

TABLE 44 OVERALL PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 45 POPULATION TRENDS, BRAZIL, THROUGH 2013 (MILLIONS)

HEALTHCARE AND HEALTH PROBLEMS IN BRAZIL

THE HEALTHCARE SYSTEM (MEDICARE)

PHARMACEUTICAL PRICING

HEALTH PROBLEMS IN BRAZIL

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 46 BRANDED PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)

GENERIC DRUGS

TABLE 47 GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ BILLIONS)

OVER-THE-COUNTER MEDICATIONS

TABLE 48 OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013 ($ MILLIONS)

IMPORTANT ORGANIZATIONS IN BRAZIL

BRAZILIAN INSTITUTE OF GEOGRAPHY AND STATISTICS

EUROPE

HEALTHCARE IN EUROPE

REIMBURSEMENT OF PHARMACEUTICALS

POPULATION DEMOGRAPHICS IN EUROPE

POPULATION GROWTH, MEDIAN AGE, AND LIFE EXPECTANCY

EXCESS WEIGHT

LIFE EXPECTANCY IN EUROPE

PHARMACEUTICAL MARKETS IN EUROPE

TABLE 49 TOP FIVE PHARMACEUTICAL MARKETS, EUROPE, THROUGH 2013 ($ BILLIONS)

PROPRIETARY PRESCRIPTION MEDICATIONS (ALSO CALLED BRANDED MEDICATIONS AND ETHICAL PHARMACEUTICALS)

TABLE 50 BRANDED PRESCRIPTION PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)

DATA EXCLUSIVITY

GENERIC MEDICATIONS

TABLE 51 GENERIC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)

GENERIC SMALL MOLECULES

BIOSIMILARS

OVER-THE-COUNTER MEDICATIONS

TABLE 52 OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)

FRANCE

INTRODUCTION

TABLE 53 OVERALL PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)

DRIVERS OF PHARMACEUTICAL SALES GROWTH

POPULATION AND DEMOGRAPHICS

TABLE 54 POPULATION TRENDS, FRANCE, THROUGH 2013 (MILLIONS)

FIGURE 6 FRANCE: POPULATION, 1998-2013 (MILLIONS)

TABLE 55 DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013 (MILLIONS)

HEALTHCARE EXPENDITURE IN FRANCE

TABLE 56 HEALTHCARE EXPENDITURE: FRANCE, 2000-2005

COMMON HEALTH PROBLEMS IN FRANCE

ALZHEIMER’S DISEASE AND RELATED DEMENTIAS

TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)

OBESITY AND RELATED CONDITIONS

DIABETES

CARDIOVASCULAR DISEASE

TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY CLASS, FRANCE, 2006 (%)

PHARMACEUTICAL PRICING

FIGURE 7 VALUE BREAKDOWN OF PHARMACEUTICALS, FRANCE, 2005 (%)

FIGURE 7 (CONTINUED)

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)

GENERIC DRUGS

TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)

FIGURE 8 LEADING GENERIC MANUFACTURERS, MARKET SHARE, FRANCE, 2006 (% SHARE)

DRIVERS AND RESTRAINTS

OVER-THE-COUNTER (OTC) MEDICATIONS IN FRANCE

TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH 2013 ($ BILLIONS)

TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS IN FRANCE (%)

EXPORT-IMPORT PROFILE

TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 ($BILLIONS)

TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 ($BILLIONS)

PHARMACEUTICAL DISTRIBUTION

WHOLESALERS

FIGURE 9 LEADING WHOLESALERS MARKET SHARE, FRANCE, 2006-2007 (% SHARE)

FRANCE’S PHARMACEUTICAL EXPORTS AND IMPORTS IN

EUROS

TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006 (EUROS, MILLIONS)

TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006 (EUROS, MILLIONS)

IMPORTANT ORGANIZATIONS IN FRANCE

INSEE (NATIONAL INSTITUTE FOR STATISTICS AND ECONOMIC STUDIES)

LEEM, THE FRENCH PHARMACEUTICAL COMPANIES ASSOCIATION

CSRP (SYNDICATE OF PHARMACEUTICAL DISTRIBUTORS:

FRANCE ALZHEIMER:

COMPANY PROFILES: FRANCE

BIOGARAN

CERP

MERCK GENERIQUES

SANDOZ: (SEE GERMANY)

SANOFI-AVENTIS

Sanofi-Aventis (Continued)

GERMANY

INTRODUCTION

TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013 (MILLIONS)

TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013 (MILLIONS)

FIGURE 10 GERMANY: POPULATION 1998-2013 (MILLIONS)

THE GERMAN HEALTHCARE SYSTEM

HEALTHCARE EXPENDITURE IN GERMANY

TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005

COMMON HEALTH PROBLEMS IN GERMANY

ALZHEIMER’S DISEASE AND RELATED DEMENTIAS

TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF PEOPLE)

OBESITY AND RELATED CONDITIONS

DIABETES

CARDIOVASCULAR DISEASE

TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY (PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)

PRICING AND REIMBURSEMENT OF PHARMACEUTICAL AGENTS

FIGURE 11 VALUE BREAKDOWN OF PHARMACEUTICALS, GERMANY, 2005 (%)

FIGURE 11 (CONTINUED)

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)

GENERIC DRUGS

TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)

DRIVERS AND RESTRAINTS

OVER-THE-COUNTER MEDICATIONS

TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH 2013 ($ BILLIONS)

TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)

PHARMACEUTICAL DISTRIBUTION

WHOLESALERS

FIGURE 12 LEADING WHOLESALERS MARKET SHARE, GERMANY, 2006-2007 (% SHARE)

GERMAN PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS

TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)

TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006 (EUROS, MILLIONS)

IMPORTANT ORGANIZATIONS IN GERMANY

DESTATIS (FEDERAL STATISTICAL OFFICE)

GERMAN FEDERAL MINISTRY FOR EDUCATION AND RESEARCH

DEUTSCHE DIABETES-UNION

PHARMA PRIVAT

BAH, BUNDESVERBAND DER ARZNEIMITTELHERSTELLER E.V

VFA, THE GERMAN ASSOCIATION OF RESEARCH-BASED PHARMACEUTICAL COMPANIES

COMPANY PROFILES: GERMANY

CELESIO AG

MERCK KGAA

SANDOZ

STADA ARZNEIMITTEL AG

UNITED KINGDOM (U.K.)

INTRODUCTION

TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)

DRIVERS OF PHARMACEUTICAL SALES GROWTH

POPULATION AND DEMOGRAPHICS

TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)

FIGURE 13 U.K. POPULATION, 1998-2013 (MILLIONS)

TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)

THE U.K. HEALTHCARE SYSTEM

HEALTHCARE EXPENDITURE IN THE U.K

TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005

COMMON HEALTH PROBLEMS IN THE U.K.

ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS

TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050 (MILLIONS OF PEOPLE)

OBESITY AND RELATED CONDITIONS

DIABETES

CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)

TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS BY TOP EIGHT CLASSES, U.K., 2006 (%)

TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, U.K., 2006 ($ MILLIONS)

BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN THE U.K. AND REVENUE BREAKDOWN

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)

TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004 (% OF TOTAL MARKET)

GENERIC DRUGS

TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)

DRIVERS AND RESTRAINTS

OVER-THE-COUNTER (OTC) MEDICATIONS IN THE U.K

TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013 ($ BILLIONS)

TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL MARKET)

EXPORT-IMPORT PROFILE

TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006 ($ BILLIONS)

PHARMACEUTICAL DISTRIBUTION

WHOLESALERS

TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (%OF TOTAL MARKET)

U.K.’S PHARMACEUTICAL EXPORTS AND IMPORTS IN POUNDS STERLING

TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£BILLIONS)

IMPORTANT ORGANIZATIONS IN THE U.K.

NATIONAL STATISTICS U.K.

ABPI, THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY

THE BRITISH ASSOCIATION OF PHARMACEUTICAL WHOLESALERS (BAPW)

COMPANY PROFILES: U.K

AAH PHARMACEUTICALS

GLAXOSMITHKLINE (GSK)

MAWDSLEY-BROOKS & CO. LTD.

PHOENIX HEALTHCARE DISTRIBUTION, LTD.

UNICHEM

Unichem (Continued)

ITALY

INTRODUCTION

TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)

DRIVERS OF PHARMACEUTICAL SALES GROWTH

POPULATION AND DEMOGRAPHICS

TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)

FIGURE 14 ITALY: POPULATION, 1998-2013 (MILLIONS)

TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013 (MILLIONS)

THE ITALIAN HEALTHCARE SYSTEM AND GROWTH DRIVERS

TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005

COMMON HEALTH PROBLEMS IN ITALY

ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS

OBESITY AND RELATED CONDITIONS

DIABETES

CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)

TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)

BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN ITALY

REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN ITALY

FIGURE 15 VALUE BREAKDOWN OF PHARMACEUTICALS, ITALY, 2005 (%)

FIGURE 15 (CONTINUED)

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)

GENERIC DRUGS

TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)

DRIVERS AND RESTRAINTS

OVER-THE-COUNTER MEDICATIONS

TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013 ($ BILLIONS)

TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL MARKET)

EXPORT-IMPORT PROFILE

TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 ($ BILLIONS, ROUNDED)

TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL EXPORTS, 2006 (% OF TOTAL MARKET)

TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 ($ BILLIONS)

TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL IMPORTS, 2006 (% OF TOTAL MARKET)

ITALY’S PHARMACEUTICAL EXPORTS AND IMPORTS IN EUROS

TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)

TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006 (€ BILLIONS)

IMPORTANT ORGANIZATIONS IN ITALY

NATIONAL INSTITUTE FOR STATISTICS (ISTITUTO NAZIONALE DI STATISTICA)

FARMINDUSTRIA, THE PHARMACEUTICAL MANUFACTURER’S ASSOCIATION OF ITALY

ASSOGENERICI, THE ITALIAN NATIONAL ASSOCIATION OF GENERIC PHARMACEUTICALS

SPAIN

INTRODUCTION

TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)

DRIVERS OF PHARMACEUTICAL SALES GROWTH

POPULATION AND DEMOGRAPHICS

TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013 (MILLIONS)

FIGURE 16 SPAIN: POPULATION, 1998-2013 (MILLIONS)

TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013 (MILLIONS)

THE SPANISH HEALTHCARE SYSTEM, PRICING, AND PHARMACEUTICAL GROWTH DRIVERS

THE HEALTHCARE SYSTEM

TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005

DRUG PRICING POLICIES

COMMON HEALTH PROBLEMS IN SPAIN

ALZHEIMER’S DISEASE (AD) AND RELATED DEMENTIAS

OBESITY AND RELATED CONDITIONS

DIABETES

CARDIOVASCULAR DISEASE (INCLUDING HEART DISEASE AND STROKE)

TABLE 113 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS, BY CLASS, SPAIN, 2006

GROWTH DRIVERS

BARRIERS TO PHARMACEUTICAL REVENUE GROWTH IN SPAIN

REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN SPAIN

FIGURE 17 VALUE BREAKDOWN OF PHARMACEUTICALS, SPAIN, 2005 (%)

FIGURE 17 (CONTINUED)

MARKET SECTORS

BRANDED PRESCRIPTION PHARMACEUTICALS

TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)

GENERIC DRUGS

TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ BILLIONS)

DRIVERS AND RESTRAINTS

OVER-THE-COUNTER MEDICATIONS

TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013 ($ MILLIONS)

EXPORT-IMPORT PROFILE

TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)

TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)

IMPORTANT ORGANIZATIONS IN SPAIN

NATIONAL STATISTICS INSTITUTE (INSTITUTO NACIONAL DE ESTADISTICA)

FARMAINDUSTRIA, THE NATIONAL ASSOCIATION OF THE PHARMACEUTICAL INDUSTRY IN SPAIN

AESEG, THE SPANISH ASSOCIATION OF GENERIC PHARMACEUTICALS MANUFACTURERS

ANEFP, THE NATIONALS ASSOCIATION OF OVER-THECOUNTER MEDICATIONS

CEAFA, CONFEDERACTION ESPANOLA DE FAMILIARES ENFERMOS DE ALZHEIMER’S Y OTRAS DEMENCIAS

SMALLER PHARMACEUTICAL MARKETS IN EUROPE

GREECE

INTRODUCTION

TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013 (MILLIONS)

FIGURE 18 GREECE: POPULATION, 1998-2013

(MILLIONS)

TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013 (MILLIONS)

THE GREEK HEALTHCARE SYSTEM

Structure of the Healthcare System

Healthcare Expenditures

TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005

COMMON HEALTH PROBLEMS IN GREECE

Pharmaceutical Pricing

TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS, BY CLASS, GREECE, 2004

REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN GREECE

FIGURE 19 VALUE BREAKDOWN OF PHARMACEUTICALS, GREECE, 2005 (%)

Growth Drivers

Barriers to Pharmaceutical Revenue Growth in Greece

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ BILLIONS)

Drivers and Restraints

Over-the-Counter Medications

TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH 2013 ($ MILLIONS)

TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL MARKET)

IMPORTANT ORGANIZATIONS IN GREECE

STATISTICS GREECE

THE HELLENIC ASSOCIATION OF PHARMACEUTICAL COMPANIES (SFEE)

EFEX, THE GREEK PROPRIETARY ASSOCIATION

THE NETHERLANDS

INTRODUCTION

TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)

FIGURE 20 NETHERLANDS: POPULATION, 1998-2013 (MILLIONS)

TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013 (MILLIONS)

THE DUTCH HEALTHCARE SYSTEM

Structure of the Healthcare System

Healthcare Expenditures

TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-2005

COMMON HEALTH PROBLEMS IN THE NETHERLANDS

Drug Pricing

REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN THE NETHERLANDS

FIGURE 21 VALUE BREAKDOWN OF PHARMACEUTICALS, NETHERLANDS, 2005 (%)

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 132 BRANDED PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 133 GENERIC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ BILLIONS)

Drivers and Restraints

Over-the-Counter Medications

TABLE 134 OTC PHARMACEUTICAL MARKET, NETHERLANDS, THROUGH 2013 ($ MILLIONS)

TABLE 135 LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF TOTAL MARKET)

IMPORTANT ORGANIZATIONS IN THE NETHERLANDS

STATISTICS NETHERLANDS

NEFARMA, THE ASSOCIATION OF INNOVATE PHARMACEUTICALS IN THE NETHERLANDS

BOGIN, THE ASSOCIATION OF DUTCH GENERIC MEDICATIONS INDUSTRY

NEPROPHARM, THE NETHERLANDS ASSOCIATION OF OVER-THE-COUNTER PRODUCTS

BELGIUM

INTRODUCTION

TABLE 136 OVERALL PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 137 POPULATION TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)

FIGURE 22 BELGIUM: POPULATION, 1998-2013 (MILLIONS)

TABLE 138 DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013 (MILLIONS)

THE BELGIAN HEALTHCARE SYSTEM

Structure of the Healthcare System

TABLE 139 HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005

COMMON HEALTH PROBLEMS IN BELGIUM

DRUG PRICING

REVENUE BREAKDOWN OF PHARMACEUTICAL PRODUCTS IN BELGIUM

FIGURE 23 VALUE BREAKDOWN OF PHARMACEUTICALS, BELGIUM, 2005 (%)

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 140 BRANDED PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 141 GENERIC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 142 OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH 2013 ($ MILLIONS)

TABLE 143 LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL MARKET)

IMPORTANT ORGANIZATIONS IN BELGIUM

STATISTICS BELGIUM

PHARMA.BE, THE GENERAL ASSOCIATION OF THE MEDICINES INDUSTRY

EUROGENERICS

POLAND

INTRODUCTION

TABLE 144 OVERALL PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 145 POPULATION TRENDS, POLAND, THROUGH 2013 (MILLIONS)

FIGURE 24 POLAND: POPULATION, 1998-2013 (MILLIONS)

TABLE 146 DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013 (MILLIONS)

COMMON HEALTH PROBLEMS IN POLAND

THE POLISH HEALTHCARE SYSTEM

Structure of the Healthcare System

TABLE 147 HEALTHCARE EXPENDITURE: POLAND, 2000-2005

DRUG PRICING

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 148 BRANDED PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 149 GENERIC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 150 OTC PHARMACEUTICAL MARKET, POLAND, THROUGH 2013 ($ MILLIONS)

TABLE 151 LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL MARKET)

IMPORTANT ORGANIZATIONS IN POLAND

POLISH CENTRAL STATISTICS OFFICE

POLFARMED, POLISH CHAMBER OF PHARMACEUTICALS INDUSTRY AND MEDICAL DEVICES

PASMI, THE POLISH ASSOCIATION OF THE SELFMEDICATION INDUSTRY

PORTUGAL

INTRODUCTION

TABLE 152 OVERALL PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 153 POPULATION TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)

FIGURE 25 PORTUGAL: POPULATION, 1998-2013 (MILLIONS)

TABLE 154 DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013 (MILLIONS)

THE PORTUGUESE HEALTHCARE SYSTEM

Structure of the Healthcare System

TABLE 155 HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005

Pharmaceutical Pricing

FIGURE 26 VALUE BREAKDOWN OF PHARMACEUTICALS, PORTUGAL, 2005 (%)

FIGURE 26 (CONTINUED)

COMMON HEALTH PROBLEMS IN PORTUGAL

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 156 BRANDED PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 157 GENERIC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 158 OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH 2013 ($ MILLIONS)

TABLE 159 LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF TOTAL MARKET)

IMPORTANT ORGANIZATIONS IN PORTUGAL

STATISTICS PORTUGAL

APOGEN, PORTUGUESE ASSOCIATION OF GENERIC MEDICATIONS

APIFARMA, THE ASSOCIATION OF THE PORTUGUESE PHARMACEUTICAL INDUSTRY

SWITZERLAND

INTRODUCTION

TABLE 160 OVERALL PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 161 POPULATION TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)

FIGURE 27 SWITZERLAND: POPULATION, 1998-2013 (MILLIONS)

TABLE 162 DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013 (MILLIONS)

Common Health Problems in Switzerland

THE SWISS HEALTHCARE SYSTEM

Structure of the Healthcare System

TABLE 163 HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005

Pharmaceutical Environment and Pricing

Pharmaceutical Environment …(Continued)

FIGURE 28 VALUE BREAKDOWN OF PHARMACEUTICALS, SWITZERLAND, 2005 (%)

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 164 BRANDED PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 165 GENERIC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 166 OTC PHARMACEUTICAL MARKET, SWITZERLAND, THROUGH 2013 ($ MILLIONS)

TABLE 167 LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF TOTAL MARKET)

IMPORTANT ORGANIZATIONS IN SWITZERLAND

SWISS FEDERAL STATISTICS OFFICE

COMPANY PROFILES

NOVARTIS INTERNATIONAL AG

SWEDEN

INTRODUCTION

TABLE 168 OVERALL PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 169 POPULATION TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)

FIGURE 29 SWEDEN: POPULATION, 1998-2013 (MILLIONS)

TABLE 170 DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013 (MILLIONS)

HEALTH PROBLEMS AND HEALTHCARE IN SWEDEN

The Healthcare System

TABLE 171 HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005

Pharmaceutical Pricing

FIGURE 30 VALUE BREAKDOWN OF PHARMACEUTICALS, SWEDEN, 2005 (%)

Health Problems in Sweden

TABLE 172 LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006 (% OF TOTAL MARKET, BY VALUE)

MARKET SECTORS

Branded Pharmaceuticals

TABLE 173 BRANDED PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 174 GENERIC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 175 OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH 2013 ($ MILLIONS)

IMPORTANT ORGANIZATIONS IN SWEDEN

STATISTICS SWEDEN

FGL, THE SWEDISH ASSOCIATION FOR GENERIC PHARMACEUTICALS

AUSTRIA

INTRODUCTION

TABLE 176 OVERALL PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 177 POPULATION TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)

FIGURE 31 AUSTRIA: POPULATION, 1998-2013 (MILLIONS)

TABLE 178 DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013 (MILLIONS)

HEALTHCARE AND HEALTH PROBLEMS IN AUSTRIA

The Healthcare System

Pharmaceutical Pricing

TABLE 179 HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005

Health Problems in Austria

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 180 BRANDED PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 181 GENERIC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 182 OTC PHARMACEUTICAL MARKET, AUSTRIA, THROUGH 2013 ($ MILLIONS)

IMPORTANT ORGANIZATIONS IN AUSTRIA

STATISTICS AUSTRIA

PHARMIG, THE

IGEPHA, THE AUSTRIAN SELF-MEDICATION INDUSTRY

HUNGARY

INTRODUCTION

TABLE 183 OVERALL PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

HEALTH PROBLEMS AND HEALTHCARE IN HUNGARY

The Healthcare System

Pharmaceutical Pricing

Health Problems in Hungary

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 184 BRANDED PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 185 GENERIC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 186 OTC PHARMACEUTICAL MARKET, HUNGARY, THROUGH 2013 ($ MILLIONS)

IMPORTANT ORGANIZATIONS IN HUNGARY

HUNGARIAN CENTRAL STATISTICS OFFICE

MAGYOSZ, THE HUNGARIAN PHARMACEUTICAL MANUFACTURERS ASSOCIATION

FINLAND

INTRODUCTION

TABLE 187 OVERALL PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 188 POPULATION TRENDS, FINLAND, THROUGH 2013 (MILLIONS)

TABLE 189 DEMOGRAPHIC TRENDS, FINLAND, THROUGH 2013 (MILLIONS)

HEALTH PROBLEMS AND HEALTHCARE IN FINLAND

The Healthcare System

PHARMACEUTICAL PRICING

Health Problems in Finland

MARKET SECTORS

TABLE 190 LEADING THERAPEUTIC CATEGORIES, FINLAND, 2006 (% OF TOTAL MARKET, BY VALUE)

Branded Prescription Pharmaceuticals

TABLE 191 BRANDED PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 192 GENERIC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 193 OTC PHARMACEUTICAL MARKET, FINLAND, THROUGH 2013 ($ MILLIONS)

IMPORTANT ORGANIZATIONS IN FINLAND

STATISTICS FINLAND

IMPORTANT ORGANIZATIONS IN EUROPE

THE EUROPEAN FEDERATION OF PHARMACEUTICAL INDUSTRIES AND ASSOCIATIONS (EFPIA)

THE EUROPEAN GENERICS ASSOCIATION (EGA)

THE ASSOCIATION OF THE EUROPEAN SELFMEDICATION INDUSTRY (AESGP)

ASIA

JAPAN

INTRODUCTION

TABLE 194 OVERALL PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 195 POPULATION TRENDS, JAPAN, THROUGH 2013 (MILLIONS)

TABLE 196 DEMOGRAPHIC TRENDS, JAPAN, THROUGH 2013 (MILLIONS)

FIGURE 32 JAPAN: POPULATION, 1998-2013 (MILLIONS)

THE JAPANESE HEALTHCARE SYSTEM

Healthcare Expenditures in Japan

TABLE 197 HEALTHCARE EXPENDITURE: JAPAN, 2000-2005

Common Health Problems in Japan

TABLE 198 LEADING CAUSES OF DEATH, JAPAN, 2005

Cancer

TABLE 199 LEADING FORMS OF CANCER, JAPAN, 2005

Alzheimer’s Disease and Related Dementias

Obesity and Diabetes

Cardiovascular Disease

Smoking

PHARMACEUTICAL PRICING

Pharmaceutical Pricing (Continued)

Pricing of Generic Drugs

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 120 BRANDED PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 201 GENERIC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)

OVER-THE-COUNTER MEDICATIONS IN JAPAN

TABLE 202 OTC PHARMACEUTICAL MARKET, JAPAN, THROUGH 2013 ($ BILLIONS)

TABLE 203 LEADING OTC CATEGORIES, JAPAN

IMPORTANT ORGANIZATIONS IN JAPAN

STATISTICS BUREAU

MINISTRY OF HEALTH, LABOUR, & WELFARE

JPMA, JAPAN PHARMACEUTICAL MANUFACTURER’S ASSOCIATION

JSMI, JAPANESE SELF-MEDICATION INDUSTRY

COMPANY PROFILES

ASTELLAS PHARMA

SAWAI PHARMACEUTICAL COMPANY LTD

TAKEDA PHARMACEUTICAL COMPANY LTD.

CHINA

INTRODUCTION

TABLE 204 OVERALL PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 205 POPULATION TRENDS, CHINA, THROUGH 2013 (MILLIONS)

TABLE 206 DEMOGRAPHIC TRENDS, CHINA, THROUGH 2013 (MILLIONS)

HEALTHCARE AND HEALTH PROBLEMS IN CHINA

The Healthcare System

Pharmaceutical Pricing

Health Problems in China

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 207 PRESCRIPTION PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ BILLIONS)

Generic Drugs

Over-the-Counter Medications

TABLE 208 OTC PHARMACEUTICAL MARKET, CHINA, THROUGH 2013 ($ MILLIONS)

IMPORTANT ORGANIZATIONS IN CHINA

NATIONAL BUREAU OF STATISTICS OF CHINA

SOUTH KOREA

INTRODUCTION

TABLE 209 OVERALL PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 210 POPULATION TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)

TABLE 211 DEMOGRAPHIC TRENDS, SOUTH KOREA, THROUGH 2013 (MILLIONS)

HEALTHCARE AND HEALTH PROBLEMS IN SOUTH KOREA

The Healthcare System

Pharmaceutical Pricing

Health Problems in South Korea

TABLE 212 LEADING CAUSES OF DEATH, SOUTH KOREA, 2003

MARKET SECTORS

Branded and Generic Prescription Pharmaceuticals

TABLE 213 PRESCRIPTION PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 214 OTC PHARMACEUTICAL MARKET, SOUTH KOREA, THROUGH 2013 ($ MILLIONS)

IMPORTANT ORGANIZATIONS IN SOUTH KOREA

KOREAN NATIONAL STATISTICAL OFFICE

AUSTRALIA

INTRODUCTION

TABLE 215 OVERALL PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 216 POPULATION TRENDS, AUSTRALIA, THROUGH 2013 (MILLIONS)

HEALTHCARE AND HEALTH PROBLEMS IN AUSTRALIA

The Healthcare System (Medicare)

Pharmaceutical Pricing

Health Problems in Australia

TABLE 217 LEADING CAUSES OF DEATH, MEN, AUSTRALIA, 2005 (% OF ALL DEATHS)

TABLE 218 LEADING CAUSES OF DEATH, WOMEN, AUSTRALIA, 2004 (% OF ALL DEATHS)

TABLE 219 COMMON CHRONIC CONDITIONS, AUSTRALIA, 2005 (% OF POPULATION)

MARKET SECTORS

Branded Prescription Pharmaceuticals

TABLE 220 BRANDED PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)

Generic Drugs

TABLE 221 GENERIC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ BILLIONS)

Over-the-Counter Medications

TABLE 222 OTC PHARMACEUTICAL MARKET, AUSTRALIA, THROUGH 2013 ($ MILLIONS)

TABLE 223 TOP OTC PURCHASES, AUSTRALIA (% OF THE POPULATION)

IMPORTANT ORGANIZATIONS IN AUSTRALIA

AUSTRALIAN BUREAU OF STATISTICS

DEPARTMENT OF INNOVATION, INDUSTRY, SCIENCE, AND RESEARCH

MEDICINES AUSTRALIA

INDIA

INTRODUCTION

TABLE 224 OVERALL PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)

POPULATION AND DEMOGRAPHICS

TABLE 225 POPULATION TRENDS, INDIA, THROUGH 2013 (MILLIONS)

HEALTHCARE AND HEALTH PROBLEMS IN INDIA

Pharmaceutical Pricing

HEALTH PROBLEMS IN INDIA

MARKET SECTORS

Overview

TABLE 226 TOP INDIAN PHARMACEUTICAL COMPANIES BY REVENUES, 2006 ($ MILLIONS)

Barriers to Growth in India

Branded Prescription Pharmaceuticals

TABLE 227 PRESCRIPTION PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)

Generics

Over-the-Counter Medications

TABLE 228 OTC PHARMACEUTICAL MARKET, INDIA, THROUGH 2013 ($ BILLIONS)

IMPORTANT ORGANIZATIONS IN INDIA

MINISTRY OF STATISTICS AND PROGRAMME IMPLEMENTATION

MINISTRY OF HEALTH

IDMA, THE INDIAN DRUG MANUFACTURERS ASSOCIATION

OPPI, THE ORGANISATION OF PHARMACEUTICAL PRODUCERS OF INDIA

COMPANY PROFILES

RANBAXY LABORATORIES, LTD

CIPLA LTD

DR. REDDY’S LABORATORIES LTD.

SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE

PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES NOT COVERED IN DETAIL IN THIS REPORT

PHARMACEUTICAL MARKETS IN SELECTED COUNTRIES …

PHARMACEUTICAL MARKETS…(CONTINUED)

SOME INTERESTING LINKS RELATED TO HEALTH, PHARMACEUTICALS, AND DISEASE

LIST OF TABLES

SUMMARY TABLE WORLDWIDE MARKET PHARMACEUTICAL

PRODUCTS, THROUGH 2013 ($ BILLIONS)

TABLE 1 HEALTHCARE EXPENDITURES, COUNTRIES IN THIS

REPORT, 2000 AND 2005 (% OF GDP)

TABLE 2 WORLDWIDE LEADING ETHICAL PHARMACEUTICAL

COMPANIES: SALES AND MARKET SHARE, 2006 AND 2007

($ BILLIONS)

TABLE 3 WORLDWIDE LEADING PHARMACEUTICAL COMPANIES BY

R&D SPENDING, 2006 AND 2007 ($ BILLIONS)

TABLE 4 LARGEST PHARMACEUTICAL MARKETS (OVERALL), 2006

AND 2007 ($ BILLIONS, % OF TOTAL)

TABLE 5 LARGEST PHARMACEUTICAL MARKETS (BRANDED), 2006

AND 2007 ($ BILLIONS, % OF TOTAL)

TABLE 6 WORLDWIDE LEADING PHARMACEUTICAL LARGEST

PHARMACEUTICAL MARKETS (GENERIC), 2006 AND 2007

($ BILLIONS, % OF TOTAL)

TABLE 7 LARGEST PHARMACEUTICAL MARKETS (OTC), 2006 AND

2007 ($ BILLIONS, % OF TOTAL)

TABLE 8 OVERALL PHARMACEUTICAL MARKET, U.S., THROUGH

2013 ($ BILLIONS)

TABLE 9 POPULATION TRENDS, U.S., THROUGH 2013 (MILLIONS)

TABLE 10 DEMOGRAPHIC TRENDS, U.S., THROUGH 2013 (MILLIONS)

TABLE 11 HEALTHCARE EXPENDITURE, U.S., 2000 AND 2006

TABLE 12 MOST EXPENSIVE MEDICAL CONDITIONS, U.S., 2004

($ BILLIONS, %)

TABLE 13 PRESCRIPTION DRUG EXPENDITURES BY CATEGORY, 2006

($ BILLIONS)

TABLE 14 LEADING CAUSES OF DEATH, U.S. 1997-2005 (%)

TABLE 15 CARDIOVASCULAR DISEASE, U.S., 2005 (%)

TABLE 16 INVASIVE CANCER, U.S., 2004 (%)

TABLE 17 CANCER DEATHS, U.S., 2004 (%)

TABLE 18 CANCER DEATHS, U.S., 2004 (RATIO OF DEATHS: NEW

CASES)

TABLE 19 NEW MOLECULAR ENTITIES APPROVED BY THE FDA,

1980 TO MARCH 20, 2007

TABLE 20 NME APPROVALS BY DISORDER, 2004-MARCH 20, 2008

TABLE 21 BOTOX SALES, 1993-2012 ($ MILLIONS)

TABLE 22 MARKET SHARE: PHARMACY BENEFIT MANAGERS, 2007

(%)

TABLE 23 MARKET SHARE: U.S. WHOLESALERS, 2007 (%, $ BILLIONS)

TABLE 24 LEADING DRUG RETAILERS RX VOLUME, U.S., 2002 AND

2007 (RX MILLIONS)

TABLE 25 EXPORT-IMPORT PROFILE, U.S., 1995-2006 ($ BILLIONS)

TABLE 26 BRANDED PHARMACEUTICAL MARKET, U.S., THROUGH

2013 ($ BILLIONS)

TABLE 27 TOP 10 SELLING U.S. DRUGS, 2006 AND 2007 ($ BILLIONS)

TABLE 28 GENERIC PRESCRIPTION PHARMACEUTICAL MARKET,

U.S., THROUGH 2013 ($ BILLIONS)

TABLE 29 OTC PHARMACEUTICAL MARKET, U.S., THROUGH 2013

($ BILLIONS)

TABLE 30 OVERALL PHARMACEUTICAL MARKET, CANADA,

THROUGH 2013 ($ BILLIONS)

TABLE 31 POPULATION TRENDS, CANADA, THROUGH 2013

(MILLIONS)

TABLE 32 DEMOGRAPHIC TRENDS, CANADA, THROUGH 2013

(MILLIONS)

TABLE 33 HEALTHCARE EXPENDITURE: CANADA, 2000 AND 2005

TABLE 34 BRANDED PHARMACEUTICAL MARKET, CANADA,

THROUGH 2013 ($ BILLIONS)

TABLE 35 GENERIC PHARMACEUTICAL MARKET, CANADA,

THROUGH 2013 ($ BILLIONS)

TABLE 36 OTC PHARMACEUTICAL MARKET, CANADA, THROUGH

2013 ($ BILLIONS)

TABLE 37 TOP SELLING CATEGORIES OF OTC MEDICATIONS IN

CANADA (%)

TABLE 38 OVERALL PHARMACEUTICAL MARKET, MEXICO,

THROUGH 2013 ($ BILLIONS)

TABLE 39 POPULATION TRENDS, MEXICO, THROUGH 2013

(MILLIONS)

TABLE 40 HEALTHCARE EXPENDITURE: MEXICO, 2000-2005

TABLE 41 BRANDED PHARMACEUTICAL MARKET, MEXICO,

THROUGH 2013 ($ BILLIONS)

TABLE 42 GENERIC PHARMACEUTICAL MARKET, MEXICO,

THROUGH 2013 ($ BILLIONS)

TABLE 43 OTC PHARMACEUTICAL MARKET, MEXICO, THROUGH

2013 ($ BILLIONS)

TABLE 44 OVERALL PHARMACEUTICAL MARKET, BRAZIL,

THROUGH 2013 ($ BILLIONS)

TABLE 45 POPULATION TRENDS, BRAZIL, THROUGH 2013

(MILLIONS)

TABLE 46 BRANDED PHARMACEUTICAL MARKET, BRAZIL,

THROUGH 2013 ($ BILLIONS)

TABLE 47 GENERIC PHARMACEUTICAL MARKET, BRAZIL, THROUGH

2013 ($ BILLIONS)

TABLE 48 OTC PHARMACEUTICAL MARKET, BRAZIL, THROUGH 2013

($ MILLIONS)

TABLE 49 TOP FIVE PHARMACEUTICAL MARKETS, EUROPE,

THROUGH 2013 ($ BILLIONS)

TABLE 50 BRANDED PRESCRIPTION PHARMACEUTICALS MARKET

BY VALUE, EUROPE, THROUGH 2013 ($ BILLIONS)

TABLE 51 GENERIC PHARMACEUTICALS MARKET BY VALUE,

EUROPE, THROUGH 2013 ($ BILLIONS)

TABLE 52 OTC PHARMACEUTICALS MARKET BY VALUE, EUROPE,

THROUGH 2013 ($ BILLIONS)

TABLE 53 OVERALL PHARMACEUTICAL MARKET, FRANCE,

THROUGH 2013 ($ BILLIONS)

TABLE 54 POPULATION TRENDS, FRANCE, THROUGH 2013

(MILLIONS)

TABLE 55 DEMOGRAPHIC TRENDS, FRANCE, THROUGH 2013

(MILLIONS)

TABLE 56 HEALTHCARE EXPENDITURE: FRANCE, 2000-2005

TABLE 57 DEMENTIA IN FRANCE, 2005-2050 (MILLIONS OF PEOPLE)

TABLE 58 PERCENTAGE OF SPENDING ON PHARMACEUTICALS BY

CLASS, FRANCE, 2006 (%)

TABLE 59 BRANDED PHARMACEUTICAL MARKET, FRANCE,

THROUGH 2013 ($ BILLIONS)

TABLE 60 GENERIC PHARMACEUTICAL MARKET, FRANCE,

THROUGH 2013 ($ BILLIONS)

TABLE 61 OTC PHARMACEUTICAL MARKET, FRANCE, THROUGH

2013 ($ BILLIONS)

TABLE 62 REASONS FOR ADULT PURCHASES OF OTC MEDICATIONS

IN FRANCE (%)

TABLE 63 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006

($ BILLIONS)

TABLE 64 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006

($ BILLIONS)

TABLE 65 PHARMACEUTICAL EXPORTS, FRANCE, 2000 AND 2006

(EUROS, MILLIONS)

TABLE 66 PHARMACEUTICAL IMPORTS, FRANCE, 2005 AND 2006

(EUROS, MILLIONS)

TABLE 67 OVERALL PHARMACEUTICAL MARKET, GERMANY,

THROUGH 2013 ($ BILLIONS)

TABLE 68 POPULATION TRENDS, GERMANY, THROUGH 2013

(MILLIONS)

TABLE 69 DEMOGRAPHIC TRENDS, GERMANY, THROUGH 2013

(MILLIONS)

TABLE 70 HEALTHCARE EXPENDITURE: GERMANY, 2000-2005

TABLE 71 DEMENTIA IN GERMANY, 2005-2050 (MILLIONS OF

PEOPLE)

TABLE 72 EXPENDITURES BY THERAPY AREA, GERMANY

(PERCENTAGE OF HEALTHCARE SPENDING, ROUNDED)

TABLE 73 BRANDED PHARMACEUTICAL MARKET, GERMANY,

THROUGH 2013 ($ BILLIONS)

TABLE 74 GENERIC PHARMACEUTICAL MARKET, GERMANY,

THROUGH 2013 ($ BILLIONS)

TABLE 75 OTC PHARMACEUTICAL MARKET, GERMANY, THROUGH

2013 ($ BILLIONS)

TABLE 76 LEADING OTC PRODUCTS, GERMANY, 2006 (%)

TABLE 77 PHARMACEUTICAL EXPORTS, GERMANY, 2005 AND 2006

(EUROS, MILLIONS)

TABLE 78 PHARMACEUTICAL IMPORTS, GERMANY, 2005 AND 2006

(EUROS, MILLIONS)

TABLE 79 OVERALL PHARMACEUTICAL MARKET, U.K., THROUGH

2013 ($ BILLIONS)

TABLE 80 POPULATION TRENDS, U.K., THROUGH 2013 (MILLIONS)

TABLE 81 DEMOGRAPHIC TRENDS, U.K., THROUGH 2013 (MILLIONS)

TABLE 82 HEALTHCARE EXPENDITURE: U.K., 2000-2005

TABLE 83 PREVALENCE OF DEMENTIA IN THE U.K. 2005-2050

(MILLIONS OF PEOPLE)

TABLE 84 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS

BY TOP EIGHT CLASSES, U.K., 2006 (%)

TABLE 85 PERCENTAGE OF PRESCRIPTION OF PHARMACEUTICALS,

BY CLASS, U.K., 2006 ($ MILLIONS)

TABLE 86 BRANDED PHARMACEUTICAL MARKET, U.K., THROUGH

2013 ($ BILLIONS)

TABLE 87 LEADING PHARMACEUTICAL COMPANIES, U.K., 2004

(% OF TOTAL MARKET)

TABLE 88 GENERIC PHARMACEUTICAL MARKET, U.K., THROUGH

2013 ($ BILLIONS)

TABLE 89 OTC PHARMACEUTICAL MARKET, U.K., THROUGH 2013

($ BILLIONS)

TABLE 90 LEADING OTC CATEGORIES, 2006, U.K. (% OF TOTAL

MARKET)

TABLE 91 PHARMACEUTICAL EXPORTS-IMPORTS, U.K., 1997-2006

($ BILLIONS)

TABLE 92 LEADING PHARMACEUTICAL DISTRIBUTORS, U.K. (% OF

TOTAL MARKET)

TABLE 93 PHARMACEUTICAL EXPORTS, U.K., 1997-2006 (£ BILLIONS)

TABLE 94 OVERALL PHARMACEUTICAL MARKET, ITALY, THROUGH

2013 ($ BILLIONS)

TABLE 95 POPULATION TRENDS, ITALY, THROUGH 2013 (MILLIONS)

TABLE 96 DEMOGRAPHIC TRENDS, ITALY, THROUGH 2013

(MILLIONS)

TABLE 97 HEALTHCARE EXPENDITURE: ITALY, 2000-2005

TABLE 98 PERCENTAGE OF CLASS C PRESCRIPTION

PHARMACEUTICALS BY CLASS, ITALY, 2006 (%)

TABLE 99 BRANDED PHARMACEUTICAL MARKET, ITALY, THROUGH

2013 ($ BILLIONS)

TABLE 100 GENERIC PHARMACEUTICAL MARKET, ITALY, THROUGH

2013 ($ BILLIONS)

TABLE 101 OTC PHARMACEUTICAL MARKET, ITALY, THROUGH 2013

($ BILLIONS)

TABLE 102 LEADING OTC CATEGORIES, ITALY, 2006 (% OF TOTAL

MARKET)

TABLE 103 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006

($ BILLIONS, ROUNDED)

TABLE 104 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL

EXPORTS, 2006 (% OF TOTAL MARKET)

TABLE 105 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006

($ BILLIONS)

TABLE 106 LEADING DESTINATIONS OF ITALIAN PHARMACEUTICAL

IMPORTS, 2006 (% OF TOTAL MARKET)

TABLE 107 PHARMACEUTICAL EXPORTS, ITALY, 2005 AND 2006

(€ BILLIONS)

TABLE 108 PHARMACEUTICAL IMPORTS, ITALY, 2005 AND 2006

(€ BILLIONS)

TABLE 109 OVERALL PHARMACEUTICAL MARKET, SPAIN, THROUGH

2013 ($ BILLIONS)

TABLE 110 POPULATION TRENDS, SPAIN, THROUGH 2013

(MILLIONS)

TABLE 111 DEMOGRAPHIC TRENDS, SPAIN, THROUGH 2013

(MILLIONS)

TABLE 112 HEALTHCARE EXPENDITURE: SPAIN, 2000-2005

TABLE 113 PERCENTAGE OF PRESCRIPTION OF

PHARMACEUTICALS, BY CLASS, SPAIN, 2006

TABLE 114 BRANDED PHARMACEUTICAL MARKET, SPAIN,

THROUGH 2013 ($ BILLIONS)

TABLE 115 GENERIC PHARMACEUTICAL MARKET, SPAIN, THROUGH

2013 ($ BILLIONS)

TABLE 116 OTC PHARMACEUTICAL MARKET, SPAIN, THROUGH 2013

($ MILLIONS)

TABLE 117 PHARMACEUTICAL EXPORTS, SPAIN, 2005 AND 2006 (%)

TABLE 118 PHARMACEUTICAL IMPORTS, SPAIN, 2005 AND 2006 (%)

TABLE 119 OVERALL PHARMACEUTICAL MARKET, GREECE,

THROUGH 2013 ($ BILLIONS)

TABLE 120 POPULATION TRENDS, GREECE, THROUGH 2013

(MILLIONS)

TABLE 121 DEMOGRAPHIC TRENDS, GREECE, THROUGH 2013

(MILLIONS)

TABLE 122 HEALTHCARE EXPENDITURE: GREECE, 2000-2005

TABLE 123 PERCENTAGE OF PRESCRIPTION PHARMACEUTICALS,

BY CLASS, GREECE, 2004

TABLE 124 BRANDED PHARMACEUTICAL MARKET, GREECE,

THROUGH 2013 ($ BILLIONS)

TABLE 125 GENERIC PHARMACEUTICAL MARKET, GREECE,

THROUGH 2013 ($ BILLIONS)

TABLE 126 OTC PHARMACEUTICAL MARKET, GREECE, THROUGH

2013 ($ MILLIONS)

TABLE 127 LEADING OTC CATEGORIES, GREECE, 2006 (% OF TOTAL

MARKET)

TABLE 128 OVERALL PHARMACEUTICAL MARKET, NETHERLANDS,

THROUGH 2013 ($ BILLIONS)

TABLE 129 POPULATION TRENDS, NETHERLANDS, THROUGH 2013

(MILLIONS)

TABLE 130 DEMOGRAPHIC TRENDS, NETHERLANDS, THROUGH 2013

(MILLIONS)

TABLE 131 HEALTHCARE EXPENDITURE: THE NETHERLANDS, 2000-

2005

TABLE 132 BRANDED PHARMACEUTICAL MARKET, NETHERLANDS,

THROUGH 2013 ($ BILLIONS)

TABLE 133 GENERIC PHARMACEUTICAL MARKET, NETHERLANDS,

THROUGH 2013 ($ BILLIONS)

TABLE 134 OTC PHARMACEUTICAL MARKET, NETHERLANDS,

THROUGH 2013 ($ MILLIONS)

TABLE 135 LEADING OTC CATEGORIES, NETHERLANDS, 2006 (% OF

TOTAL MARKET)

TABLE 136 OVERALL PHARMACEUTICAL MARKET, BELGIUM,

THROUGH 2013 ($ BILLIONS)

TABLE 137 POPULATION TRENDS, BELGIUM, THROUGH 2013

(MILLIONS)

TABLE 138 DEMOGRAPHIC TRENDS, BELGIUM, THROUGH 2013

(MILLIONS)

TABLE 139 HEALTHCARE EXPENDITURE: BELGIUM, 2000-2005

TABLE 140 BRANDED PHARMACEUTICAL MARKET, BELGIUM,

THROUGH 2013 ($ BILLIONS)

TABLE 141 GENERIC PHARMACEUTICAL MARKET, BELGIUM,

THROUGH 2013 ($ BILLIONS)

TABLE 142 OTC PHARMACEUTICAL MARKET, BELGIUM, THROUGH

2013 ($ MILLIONS)

TABLE 143 LEADING OTC CATEGORIES, BELGIUM, 2006 (% OF TOTAL

MARKET)

TABLE 144 OVERALL PHARMACEUTICAL MARKET, POLAND,

THROUGH 2013 ($ BILLIONS)

TABLE 145 POPULATION TRENDS, POLAND, THROUGH 2013

(MILLIONS)

TABLE 146 DEMOGRAPHIC TRENDS, POLAND, THROUGH 2013

(MILLIONS)

TABLE 147 HEALTHCARE EXPENDITURE: POLAND, 2000-2005

TABLE 148 BRANDED PHARMACEUTICAL MARKET, POLAND,

THROUGH 2013 ($ BILLIONS)

TABLE 149 GENERIC PHARMACEUTICAL MARKET, POLAND,

THROUGH 2013 ($ BILLIONS)

TABLE 150 OTC PHARMACEUTICAL MARKET, POLAND, THROUGH

2013 ($ MILLIONS)

TABLE 151 LEADING OTC CATEGORIES, POLAND, 2006 (% OF TOTAL

MARKET)

TABLE 152 OVERALL PHARMACEUTICAL MARKET, PORTUGAL,

THROUGH 2013 ($ BILLIONS)

TABLE 153 POPULATION TRENDS, PORTUGAL, THROUGH 2013

(MILLIONS)

TABLE 154 DEMOGRAPHIC TRENDS, PORTUGAL, THROUGH 2013

(MILLIONS)

TABLE 155 HEALTHCARE EXPENDITURE: PORTUGAL, 2000-2005

TABLE 156 BRANDED PHARMACEUTICAL MARKET, PORTUGAL,

THROUGH 2013 ($ BILLIONS)

TABLE 157 GENERIC PHARMACEUTICAL MARKET, PORTUGAL,

THROUGH 2013 ($ BILLIONS)

TABLE 158 OTC PHARMACEUTICAL MARKET, PORTUGAL, THROUGH

2013 ($ MILLIONS)

TABLE 159 LEADING OTC CATEGORIES, PORTUGAL, 2006 (% OF

TOTAL MARKET)

TABLE 160 OVERALL PHARMACEUTICAL MARKET, SWITZERLAND,

THROUGH 2013 ($ BILLIONS)

TABLE 161 POPULATION TRENDS, SWITZERLAND, THROUGH 2013

(MILLIONS)

TABLE 162 DEMOGRAPHIC TRENDS, SWITZERLAND, THROUGH 2013

(MILLIONS)

TABLE 163 HEALTHCARE EXPENDITURE: SWITZERLAND, 2000-2005

TABLE 164 BRANDED PHARMACEUTICAL MARKET, SWITZERLAND,

THROUGH 2013 ($ BILLIONS)

TABLE 165 GENERIC PHARMACEUTICAL MARKET, SWITZERLAND,

THROUGH 2013 ($ BILLIONS)

TABLE 166 OTC PHARMACEUTICAL MARKET, SWITZERLAND,

THROUGH 2013 ($ MILLIONS)

TABLE 167 LEADING OTC CATEGORIES, SWITZERLAND, 2006 (% OF

TOTAL MARKET)

TABLE 168 OVERALL PHARMACEUTICAL MARKET, SWEDEN,

THROUGH 2013 ($ BILLIONS)

TABLE 169 POPULATION TRENDS, SWEDEN, THROUGH 2013

(MILLIONS)

TABLE 170 DEMOGRAPHIC TRENDS, SWEDEN, THROUGH 2013

(MILLIONS)

TABLE 171 HEALTHCARE EXPENDITURE: SWEDEN, 2000-2005

TABLE 172 LEADING THERAPEUTIC CATEGORIES, SWEDEN, 2006

(% OF TOTAL MARKET, BY VALUE)

TABLE 173 BRANDED PHARMACEUTICAL MARKET, SWEDEN,

THROUGH 2013 ($ BILLIONS)

TABLE 174 GENERIC PHARMACEUTICAL MARKET, SWEDEN,

THROUGH 2013 ($ BILLIONS)

TABLE 175 OTC PHARMACEUTICAL MARKET, SWEDEN, THROUGH

2013 ($ MILLIONS)

TABLE 176 OVERALL PHARMACEUTICAL MARKET, AUSTRIA,

THROUGH 2013 ($ BILLIONS)

TABLE 177 POPULATION TRENDS, AUSTRIA, THROUGH 2013

(MILLIONS)

TABLE 178 DEMOGRAPHIC TRENDS, AUSTRIA, THROUGH 2013

(MILLIONS)

TABLE 179 HEALTHCARE EXPENDITURE: AUSTRIA, 2000-2005